Radiopharm Theranostics Limited (RADX), on Monday announced promising new data from the European Molecular Imaging Meeting or EMIM 2025, showcasing the potential of 68Ga-RAD202 for imaging and 177Lu-RAD202 for therapy in HER2-positive solid tumors.
HER2-positive cancers, such as certain types of breast cancer, are aggressive and often have limited treatment options.
RAD202 represents a novel approach targeting the HER2 receptor using radiopharmaceuticals.
The data revealed that 68Ga-RAD202 effectively binds to HER2 in tumors, demonstrating high tumor-to-background ratios in imaging, with low uptake in non-target organs, except for the bladder and kidneys, as expected.
Furthermore, 177Lu-RAD202 therapy resulted in a significant reduction in tumor volume and improved survival rates, with fractionated dosing proving more effective than a single-dose regimen.
Key findings include:
--- 68Ga-RAD202 showed specific accumulation in HER2-positive tumors, enhancing imaging with a favorable tumor-to-organ ratio.
-- Treatment with 177Lu-RAD202 led to tumor volume reduction and extended survival, with fractionated dosing being more effective than single-dose therapy.
-- The data further supports the ongoing Phase 1 trial of 177Lu-RAD202 in HER2-positive advanced solid tumors, currently recruiting patients in Australia.
These findings underscore the potential of RAD202 to provide a novel treatment option for patients with HER2-positive cancers, especially those who have not responded to or cannot tolerate current therapies.
Currently, RADX is trading at $6.29 up by 8.45 percent on the Nasdaq.
For comments and feedback: editorial@rttnews.com